Formulation and Evaluation of Mouth Dissolving Tablets of Nebivolol HCL for Treatment of Hypertension

Abstract

The present study was aimed at the formulation and evaluation of mouth dissolving tablets (MDTs) of Nebivolol HCl for the effective treatment of hypertension, enhancing patient compliance and ensuring rapid onset of action. Nebivolol HCl, a β1-selective adrenergic blocker, suffers from poor aqueous solubility, which limits its bioavailability. To address this, mouth dissolving tablets were formulated using different super disintegrants — Polyplasdone XL, Solutab, and Explotab — in varying concentrations to optimize disintegration time and drug release profile.

A Total of Nine formulations (F1 to F9) were prepared by direct compression method and evaluated for pre-compression and post-compression parameters such as hardness, friability, weight variation, disintegration time, wetting time, and in vitro drug release. Among all the formulations, Formulation F3, containing an optimized concentration of Polyplasdone XL, demonstrated the most desirable results with 99.24% drug release within 30 minutes, fastest disintegration time, and excellent tablet characteristics.

The study concluded that the use of suitable super disintegrants significantly improved the dissolution rate and patient acceptability of Nebivolol HCl MDTs. Formulation F3 was identified as the optimized formulation and holds potential for rapid and effective hypertension management through improved bioavailability and patient compliance.